Stock Events

Stock Events

Liquidia 

$37.64
0
+$2.25+6.36% Wednesday 02:45

Statistics

Day High
37.64
Day Low
37.6
52W High
-
52W Low
-
Volume
66
Avg. Volume
-
Mkt Cap
3.27B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.39
-0.14
0.12
0.37
Expected EPS
0.3692
Actual EPS
N/A

Financials

-931.65%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
27.99MRevenue
-260.79MNet Income

Analyst Ratings

$46.83Average Price Target
The highest estimate is 55.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
0%
Sell
17%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LQDA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Innoviva
INVA
Mkt Cap1.15B
Innoviva focuses on the development and commercialization of pharmaceuticals, directly competing in the respiratory and pulmonary market similar to Liquidia's focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in creating therapies for cystic fibrosis, a direct competition to Liquidia's pulmonary disease treatments.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline produces a wide range of pharmaceuticals, including treatments for respiratory diseases, directly competing with Liquidia's product offerings.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a global biopharmaceutical company focusing on various therapeutic areas, including respiratory diseases, making it a competitor to Liquidia.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. offers a broad portfolio of drugs, including treatments for respiratory conditions, competing in the same space as Liquidia.
Pfizer
PFE
Mkt Cap140.15B
Pfizer develops and manufactures drugs and vaccines, including for respiratory diseases, positioning it as a competitor to Liquidia.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on advanced therapies for serious diseases, including pulmonary conditions, making it a competitor in the same therapeutic area as Liquidia.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovative treatments in several areas, including respiratory diseases, competing with Liquidia's developments.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries specializes in generic and specialty medicines, including for respiratory conditions, making it a competitor to Liquidia.
Novartis
NVS
Mkt Cap237.61B
Novartis focuses on a wide range of healthcare areas, including respiratory diseases, directly competing with Liquidia's therapeutic focus.

About

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Show more...
CEO
ISIN
US53635D2027

Listings

XNAS
US
LQDA
F
DE
LT4.F
BOATS
BOATS
LQDA.BOATS

0 Comments

Share your thoughts

FAQ

What is Liquidia stock price today?▼
The current price of LQDA.BOATS is $37.64 USD — it has increased by +6.36% in the past 24 hours. Watch Liquidia stock price performance more closely on the chart.
What is Liquidia stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Liquidia stocks are traded under the ticker LQDA.BOATS.
What is Liquidia market cap?▼
Today Liquidia has the market capitalization of 3.27B
When is the next Liquidia earnings date?▼
Liquidia is going to release the next earnings report on May 07, 2026.
What were Liquidia earnings last quarter?▼
LQDA.BOATS earnings for the last quarter are 0.15 USD per share, whereas the estimation was 0.23 USD resulting in a -33.94% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Liquidia revenue for the last year?▼
Liquidia revenue for the last year amounts to 27.99M USD.
What is Liquidia net income for the last year?▼
LQDA.BOATS net income for the last year is -260.79M USD.
When did Liquidia complete a stock split?▼
Liquidia has not had any recent stock splits.